InspireMD, Inc. (NSPR) Discusses Carotid Artery Disease Management and CGuard Prime Clinical Benefits Transcript
InspireMD, Inc. (NSPR) Discusses Carotid Artery Disease Management and CGuard Prime Clinical Benefits November 19, 2026 4:30 PM EST
Company Participants
Marvin Slosman – President, CEO & Director
Conference Call Participants
Christopher Metzger
Dimitrios Koudoumas
Peter Soukas
Patrick Geraghty
Adam Maeder – Piper Sandler & Co., Research Division
Frank Takkinen – Lake Street Capital Markets, LLC, Research Division
Marie Thibault – BTIG, LLC, Research Division
Presentation
Operator
Good afternoon, everyone, and welcome to the InspireMD Virtual KOL event. [Operator Instructions] As a reminder, this event is being recorded, and a replay will be made available on the InspireMD website following the conclusion of the event. I would now like to turn the call over to Marvin Slosman, Chief Executive Officer of InspireMD. Please go ahead, Marvin.
Marvin Slosman
President, CEO & Director
Thanks, Sarah. Thanks so much to everyone for joining us this evening. On behalf of the entire group at InspireMD, we appreciate both your joining as well as these distinguished physicians for spending some time with us this evening during what one could argue is one of the more busy and popular VEITH conferences while we figured we’d assemble this group of folks to have a chat this evening and talk to the world about the carotid space and the field in general and how that evolution has taken place.
So with me tonight is Dr. Dimitrios Koudoumas, vascular surgeon from Benefis Health System in Montana; Dr. Chris Metzger from Ballad Health System in Kingsport, Tennessee; and Peter Soukas — Dr. Peter Soukas from Brown University Health is joining us online. We could and possibly will have joining us Dr. Pat Muck, who is in the process of leading a session over at the VEITH conference. Dr. Patrick Geraghty, who’s also intending on joining us, and possibly Dr. Adnan Siddiqui, but we’ll go ahead and get started with this group of folks, and we’ll go from there.
